INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD)
© 2026 IJNRD | Volume 11, Issue 7, July 2026 | ISSN: 2456-4184 | IJNRD.ORG

Artificial Intelligence in Drug Discovery: Emerging Technologies, Explainable AI and Future Perspectives

Atish Chopdar[1], Pratibha Adnaik[2], Aarti Varne[3], Rohit Nalwade[4], Rushikesh Vadar[5]

[1,4,5]Final year M.Pharm Student, Department of Pharmaceutical Chemistry, Anandi Pharmacy College, Kalambe Tarf Kale, Kolhapur, Maharashtra, India

[2,3]Assistant Professor, Department of Pharmaceutical Chemistry, Anandi Pharmacy College, Kalambe Tarf Kale, Kolhapur, Maharashtra, India

Abstract

prediction Artificial Intelligence (AI) has revolutionized the drug discovery process by accelerating target identification, virtual screening, lead optimization, ADMET prediction, and clinical decision-making. Recent advances in Machine Learning (ML), Deep Learning (DL), Generative AI, and Explainable AI (XAI) have significantly improved the efficiency, accuracy, and cost-effectiveness of pharmaceutical research. This review discusses the role of AI across the drug discovery pipeline, recent technological advances, current challenges, ethical considerations, and future perspectives. AI has emerged as a powerful tool for modern pharmaceutical innovation; however, successful implementation requires high-quality data, rigorous validation, transparency, and regulatory acceptance.

Artificial Intelligence (AI) has emerged as a transformative technology in modern drug discovery by improving the speed, accuracy, and efficiency of pharmaceutical research. Conventional drug discovery is a lengthy, expensive, and complex process with a high failure rate. AI-driven approaches, including machine learning, deep learning, natural language processing, and generative AI, have significantly enhanced various stages of the drug discovery pipeline, such as target identification, virtual screening, molecular docking, quantitative structure–activity relationship (QSAR) modeling, lead optimization, and ADMET. These technologies enable researchers to analyze large biological datasets, identify potential drug candidates, and optimize compounds with improved precision while reducing both time and development costs. This review highlights the recent advancements, applications, challenges, and future perspectives of AI in drug discovery, with particular emphasis on explainable AI and emerging technologies. Despite challenges related to data quality, model interpretability, and regulatory acceptance, AI continues to reshape pharmaceutical research and accelerate the development of safer and more effective therapeutics. The integration of AI with human expertise is expected to play a pivotal role in the future of precision medicine and innovative drug development.

Keywords: Artificial Intelligence, Drug Discovery, Machine Learning, Deep Learning, Generative AI, Explainable AI, ADMET, Precision Medicine

1. Introduction

Drug discovery is a complex, time-consuming, and expensive process that involves the identification, design, optimization, and development of new therapeutic agents for the prevention and treatment of diseases. Traditionally, the drug discovery pipeline requires 10–15 years of research and substantial financial investment, with only a small proportion of candidate molecules successfully reaching regulatory approval. High failure rates during preclinical and clinical development, together with increasing research costs, have encouraged the pharmaceutical industry to adopt innovative computational approaches that improve research efficiency and decision-making.

Artificial Intelligence (AI) has emerged as one of the most promising technologies in pharmaceutical research by enabling data-driven decision-making throughout the drug discovery pipeline. AI integrates Machine Learning (ML), Deep Learning (DL), Natural Language Processing (NLP), Computer Vision, and Generative AI to analyze large-scale biological, chemical, and clinical datasets. These computational approaches facilitate target identification, virtual screening, molecular property prediction, lead optimization, ADMET assessment, and clinical trial optimization with greater speed and accuracy than conventional methods.

The integration of Artificial Intelligence into drug discovery has significantly reduced the time and cost associated with pharmaceutical research. AI-driven computational models can rapidly analyze millions of chemical compounds, predict biological activity, identify potential drug candidates, and optimize lead molecules before laboratory validation. These capabilities improve research productivity, reduce experimental failures, and increase the probability of successful drug development.

Recent advancements in Explainable Artificial Intelligence (XAI) and Generative Artificial Intelligence (Generative AI) have further transformed computational drug discovery. XAI improves the transparency and interpretability of AI models, enabling researchers to understand the reasoning behind predictions. In contrast, Generative AI facilitates de novo molecular design by creating novel compounds with optimized pharmacological properties, thereby accelerating the identification of innovative therapeutic candidates.

This review provides a comprehensive overview of the applications of Artificial Intelligence in modern drug discovery and development. It discusses recent advances in Machine Learning, Deep Learning, Generative AI, and Explainable AI across different stages of the drug discovery pipeline, highlights current challenges and limitations, and presents future perspectives for AI-assisted pharmaceutical research.

2. Objectives

1. To understand the role of Artificial Intelligence (AI) in modern drug discovery.
2. To study the applications of AI in target identification, virtual screening, molecular docking, QSAR modeling, lead optimization, and ADMET prediction.
3. To evaluate the impact of Machine Learning (ML), Deep Learning (DL), and Generative AI on accelerating drug discovery.
4. To analyze the advantages, challenges, and limitations of AI-based drug discovery approaches.
5. To explore the future perspectives of Artificial Intelligence in pharmaceutical research and drug development.

3. Artificial Intelligence in Drug Discovery

3.1 Drug Discovery Process

Drug discovery is a systematic and multidisciplinary process aimed at identifying, developing, and optimizing new therapeutic agents for the prevention and treatment of diseases. The traditional drug discovery pipeline involves several interconnected stages, including target identification, target validation, hit identification, lead optimization, preclinical studies, clinical trials, regulatory approval, and post-marketing surveillance. This process generally requires 10–15 years and substantial financial investment before a new drug reaches the market.

Advances in Artificial Intelligence (AI) have significantly transformed the conventional drug discovery process by improving the speed, accuracy, and efficiency of each stage. AI-based computational models enable researchers to analyze large biological datasets, predict molecular interactions, identify promising drug candidates, and optimize lead compounds while reducing experimental costs and development time.

The drug discovery pipeline begins with target identification, where biological molecules associated with a disease are identified. This is followed by target validation to confirm their therapeutic relevance. Subsequently, large chemical libraries are screened to identify potential hit compounds, which are further optimized into lead molecules through medicinal chemistry approaches before undergoing preclinical and clinical evaluation.

Artificial Intelligence supports every stage of this pipeline by integrating computational models with biological and chemical data. Machine Learning algorithms improve target prediction, Deep Learning accelerates virtual screening, Generative AI designs novel molecular structures, and Explainable AI enhances the transparency of predictive models, thereby increasing confidence in AI-assisted drug discovery.

The drug discovery pipeline begins with target identification, where researchers identify genes, proteins, or biological pathways associated with a disease. After identifying a suitable target, target validation confirms its

role in disease progression and evaluates its potential as a therapeutic intervention. This stage is essential for ensuring that the selected target can produce the desired clinical outcome.

Following target validation, researchers perform hit identification by screening large chemical libraries using experimental and computational techniques. Promising hit compounds are further optimized through medicinal chemistry to improve their potency, selectivity, pharmacokinetic properties, and safety. The optimized lead compounds then undergo preclinical evaluation, including in vitro and in vivo studies, before entering clinical trials in humans.

Artificial Intelligence has significantly improved every stage of this pipeline. Machine Learning algorithms analyze complex biological datasets for target identification, Deep Learning accelerates virtual screening and molecular property prediction, Generative AI designs novel drug-like molecules, and Explainable AI enhances the transparency of predictive models. These technologies reduce development time, minimize costs, and improve the success rate of drug discovery.



Figure 1. AI-Assisted Drug Discovery Pipeline.

3.2 Target Identification using Artificial Intelligence

Target identification is the first and one of the most important stages of drug discovery. It involves identifying biological molecules such as proteins, genes, or enzymes that are responsible for causing a disease. Selecting the correct target increases the probability of developing safe and effective drugs.

Artificial Intelligence significantly improves target identification by analyzing large-scale biological data obtained from genomics, proteomics, transcriptomics, and biomedical literature. Machine Learning algorithms recognize hidden patterns and predict disease-associated targets with higher accuracy than conventional computational methods.

Deep Learning models further enhance target identification by integrating multi-omics datasets and identifying complex biological relationships. AI also assists researchers in prioritizing potential drug targets, reducing experimental efforts, lowering research costs, and accelerating the overall drug discovery process.



Figure 2. AI-Based Target Identification Process.

3.3 Virtual Screening using Artificial Intelligence

Virtual screening is a computational technique used to identify promising drug candidates from millions of chemical compounds. It is one of the most important applications of Artificial Intelligence in modern drug discovery because it significantly reduces the time and cost required for experimental screening.

Artificial Intelligence utilizes Machine Learning and Deep Learning algorithms to predict the binding affinity between drug molecules and biological targets. AI models rapidly analyze large chemical libraries, prioritize potential compounds, and eliminate molecules with poor therapeutic potential before laboratory testing.

AI-based virtual screening improves prediction accuracy, reduces false-positive results, and accelerates lead identification. Deep learning models, molecular docking, and structure-based virtual screening enable researchers to discover novel drug candidates with higher efficiency and reliability



Figure 2. AI-Based Virtual Screening Workflow for Drug Discovery.

3.4 Molecular Docking using Artificial Intelligence

Molecular docking is a computational technique used to predict the interaction between a drug molecule and its biological target. Artificial Intelligence enhances molecular docking by improving binding affinity prediction, docking accuracy, and computational speed.

AI algorithms analyze protein structures, ligand conformations, and molecular interactions to identify the best binding poses. Machine Learning models reduce false-positive predictions and improve the reliability of docking results by learning from previously validated datasets.

AI-assisted molecular docking accelerates lead identification, improves drug-target interaction analysis, and supports structure-based drug design. Integration of AI with molecular docking enables researchers to discover potential therapeutic compounds more efficiently while reducing research costs and development time.



Figure 3. AI-Assisted Molecular Docking Workflow

3.5 QSAR (Quantitative Structure–Activity Relationship) using Artificial Intelligence

Quantitative Structure–Activity Relationship (QSAR) is a computational method that correlates the chemical structure of compounds with their biological activity. Artificial Intelligence enhances QSAR by identifying complex relationships between molecular descriptors and biological responses with greater accuracy.

Machine Learning algorithms such as Random Forest, Support Vector Machine, Artificial Neural Networks, and Deep Learning are widely used in AI-based QSAR modeling. These models analyze large datasets to predict biological activity, toxicity, and pharmacokinetic properties of new compounds.



Figure.4 QSAR (Quantitative Structure–Activity Relationship) using Artificial Intelligence

AI-powered QSAR significantly reduces the time and cost of drug discovery by enabling rapid virtual screening of chemical libraries and prioritizing promising drug candidates for experimental validation. It also improves prediction reliability and supports the development of safer and more effective therapeutic agents.

3.6 Lead Optimization using Artificial Intelligence

Lead optimization is a critical stage in drug discovery where promising lead compounds are chemically modified to improve their potency, selectivity, safety, and pharmacokinetic properties. The primary objective is to develop drug candidates with optimal therapeutic efficacy and minimal adverse effects.

Artificial Intelligence significantly enhances lead optimization by predicting molecular properties, biological activity, toxicity, and ADMET characteristics using Machine Learning and Deep Learning models. AI algorithms rapidly evaluate thousands of molecular modifications and identify the most promising candidates for further development.

AI-assisted lead optimization reduces the number of experimental iterations, shortens development time, lowers research costs, and improves decision-making during medicinal chemistry optimization. These advances increase the likelihood of successfully developing safe and effective drug candidates.



Figure 5. AI-Assisted Lead Optimization Workflow

3.7 ADMET Prediction using Artificial Intelligence

ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) prediction is a crucial stage in drug discovery because it determines whether a drug candidate is likely to be safe and effective in humans. Early prediction of ADMET properties reduces the risk of late-stage drug failure and minimizes development costs.

Artificial Intelligence uses Machine Learning and Deep Learning algorithms to accurately predict ADMET properties from molecular structures. AI models analyze large pharmacological datasets to estimate oral bioavailability, blood–brain barrier permeability, metabolic stability, toxicity, and drug–drug interactions before experimental testing.

AI-assisted ADMET prediction improves decision-making during lead optimization, reduces unnecessary laboratory experiments, accelerates candidate selection, and increases the probability of clinical success. These computational approaches have become an essential component of modern AI-driven drug discovery.



Figure 6. AI-Based ADMET Prediction Workflow

3.8 Generative AI in Drug Design

Generative Artificial Intelligence (Generative AI) has emerged as a revolutionary approach in modern drug discovery. Unlike traditional computational methods, Generative AI can design entirely new drug-like molecules with desired biological and physicochemical properties. It uses advanced deep learning models to generate novel chemical structures that may serve as potential drug candidates.

Generative AI models such as Variational Autoencoders (VAEs), Generative Adversarial Networks (GANs), Diffusion Models, and Transformer-based architectures learn from large chemical datasets to create innovative molecular structures. These models optimize molecular properties, improve drug-likeness, and reduce the need for extensive experimental synthesis and screening.

The integration of Generative AI with molecular docking, virtual screening, and ADMET prediction enables researchers to accelerate drug discovery while reducing cost and development time. This technology has shown great potential in discovering novel therapeutics for cancer, infectious diseases, neurological disorders, and rare diseases



Figure .7 Generative AI in Drug Design

4. Application Of Artificial Intelligence In Drug Discovery

Artificial Intelligence (AI) has transformed the pharmaceutical industry by improving the speed, accuracy, and efficiency of drug discovery and development. The major applications of AI are described below:

a. Drug Repurposing

AI identifies new therapeutic uses for existing drugs by analyzing biological and clinical data. This reduces development time, cost, and the risk associated with developing new drugs.

b. Personalized Medicine

AI analyzes genetic, clinical, and lifestyle data to recommend personalized treatment plans, improving treatment effectiveness and reducing adverse drug reactions.

c. Clinical Trial Optimization

AI helps in selecting suitable patients, predicting trial outcomes, monitoring patient safety, and reducing the duration and cost of clinical trials.

d. Biomarker Discovery

AI identifies biomarkers from genomic, proteomic, and clinical datasets, enabling early disease diagnosis and supporting targeted therapy development.

e. Precision Medicine

AI integrates patient-specific information with disease characteristics to design precise treatment strategies, leading to better clinical outcomes and improved patient care.

5. Challenges and Limitations of AI in Drug Discovery

Despite its remarkable advantages, Artificial Intelligence faces several challenges in drug discovery. The performance of AI models depends heavily on the availability of high-quality, diverse, and well-annotated datasets. Incomplete, biased, or inconsistent data can significantly reduce prediction accuracy and affect the reliability of AI-assisted decision-making.

Another major limitation is the lack of interpretability of complex AI models, particularly deep learning algorithms. Many models function as "black boxes," making it difficult for researchers to understand the reasoning behind their predictions. Regulatory acceptance, data privacy, ethical concerns, computational costs, and integration with experimental validation also remain important challenges.

Continuous improvements in Explainable Artificial Intelligence (XAI), standardized databases, robust validation strategies, and interdisciplinary collaboration are expected to overcome these limitations. Addressing these challenges will enhance the reliability, transparency, and widespread adoption of AI in pharmaceutical research and drug discovery.



Figure 8. Challenges and Limitations of AI in Drug Discovery

6. Future Perspectives

Artificial Intelligence is expected to play an increasingly important role in the future of drug discovery. Emerging technologies such as Generative AI, Explainable AI (XAI), Digital Twins, Quantum Computing, and Multi-omics integration will further improve the efficiency, accuracy, and speed of pharmaceutical research. AI is also expected to support personalized medicine by enabling the development of patient-specific therapeutic strategies.

Future advancements will focus on improving data quality, model transparency, regulatory acceptance, and collaboration between academia, industry, and healthcare organizations. The integration of AI with robotics, automation, and cloud computing will accelerate the discovery of safer and more effective medicines.



Figure 9. Future Perspectives of AI in Drug Discovery

7. Conclusion

Artificial Intelligence has transformed the traditional drug discovery process by improving target identification, virtual screening, molecular docking, QSAR modeling, lead optimization, ADMET prediction, and de novo drug design. AI-driven approaches significantly reduce research time, development costs, and experimental failures while improving prediction accuracy and decision-making.

Despite existing challenges related to data quality, explainability, regulatory acceptance, and computational requirements, continuous technological advancements are making AI more reliable and practical for pharmaceutical research. Overall, Artificial Intelligence represents a powerful and promising technology that will continue to shape the future of drug discovery and accelerate the development of innovative medicines for global healthcare.

7. References

1. Gawehen E, Hiss JA, Schneider G. Deep learning in drug discovery. Molecular Informatics. 2016;35:3–14.
2. Zhang L, Tan J, Han D, Zhu H. From machine learning to deep learning: progress in machine intelligence for rational drug discovery. Drug Discovery Today. 2017;22:1680–1685.
3. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discovery Today. 2018;23:1241–1250.
4. Tang W, Chen J, Wang Z, Xie H, Hong H. Deep learning for predicting toxicity of chemicals: A mini review. Journal of Environmental Science and Health, Part C. 2018;36:252–271.
5. Yang X, Wang Y, Byrne R, Schneider G, Yang S. Concepts of artificial intelligence for computer-assisted drug discovery. Chemical Reviews. 2020;120:10520–10694.
6. Muratov EN, et al. QSAR without borders. Chemical Society Reviews. 2020;49:3525–3564.
7. Hemmerich J, Ecker G. In silico toxicology: From structure-activity relationships towards deep learning and adverse outcome pathways. WIREs Computational Molecular Science. 2020;10:e1475.
8. Webb S, Hansen T, Howlin B, Krause P, Vessey J. Feature combination networks for the interpretation of statistical machine learning models: Application to Ames mutagenicity. Journal of Cheminformatics. 2020;6:1–21.
9. Grisoni F, Consonni V, Ballabio D. Machine learning consensus to predict the binding to the androgen receptor within the CoMPARA project. Journal of Chemical Information and Modeling. 2019;59:1839–1848.
10. Polishchuk P, et al. Structural and physicochemical interpretation (SPCI) of QSAR models and its comparison with matched molecular pair analysis. Journal of Chemical Information and Modeling. 2016;56:1455–1469.
11. Yang J, et al. Improved protein structure prediction using predicted inter-residue orientations. Proceedings of the National Academy of Sciences (PNAS). 2020;117:1496–1503.

12. Senior AW, et al. Improved protein structure prediction using potentials from deep learning. Nature. 2020;577:706–710.

13. Zhang X, et al. Target identification among known drugs by deep learning from heterogeneous networks. Chemical Science. 2020;11:1775–1797.

14. Jimenez J, et al. Pathwaymap: Molecular pathway association with self-normalizing neural networks. Journal of Chemical Information and Modeling. 2018;59:1172–1181.

15. Marchese Robinson RL, Palczewska A, Palczewski J, Kidley N. Comparison of the predictive performance and interpretability of random forest and linear models on benchmark data sets. Journal of Chemical Information and Modeling. 2017;57:1773–1792.

16. Zhang K, Yang X, Wang Y, Yu Y, Huang N, Li G, et al. Artificial intelligence in drug development. Nat Med. 2025;31:45–59. doi:10.1038/s41591-024-03434-4.

17. Mullard A. When can AI deliver the drug discovery hits? Nat Rev Drug Discov. 2024;23:159–161. doi:10.1038/d41573-024-00036-0.

18. Durant G, Boyles F, Birchall K, Deane CM, et al. The future of machine learning for small-molecule drug discovery will be driven by data. Nat Comput Sci. 2024;4:735–743.

19. Gangwal A, Ansari A, Ahmad I, Azad AK, Kumarasamy V, Subramaniyan V, et al. Generative artificial intelligence in drug discovery: basic framework, recent advances, challenges, and opportunities. Front Pharmacol. 2024;15:1331062. doi:10.3389/fphar.2024.1331062.

20. Kant S, Deepika, Roy S. Artificial intelligence in drug discovery and development: transforming challenges into opportunities. Discover Pharmaceutical Sciences. 2025;1:7.